| | | 重庆正川医药包装材料股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 在不影响公司日常经营活动，确保资金安全性、流动性的前提下，对公司闲 置自有资金进行现金管理，进一步提高资金使用效率，增加公司和股东收益。 重要内容提示： 现金管理产品提供方：渝农商理财有限责任公司（以下简称"渝农商理 财"）； 现金管理产品名称：渝农商理财益尊封闭式2023年第32008期； 现金管理金额：共计5,000万元； 现金管理期限：99天； 履行的审议程序：公司于2023年6月30日召开了第四届董事会第七次会议、 第四届监事会第五次会议，审议通过了《关于使用闲置自有资金进行现金管理的 议案》，同意公司使用额度不超过人民币25,000万元的闲置自有资金进行现金管 理，以上资金额度在董事会审议通过之日起12个月内可以循环滚动使用。 一、本次现金管理概况 （一）目的 （二）资金来源 本次现金管理的资金全部来源于闲置自有资金。 （三）现金管理产品的基本情况 | 产品提 | 产品类型 | 产 ...

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-047 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于"正川转债"预计满足转股价格修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、可转债发行上市概况 经中国证券监督管理委员会证监许可[2021]198号《关于核准重庆正川医药 包装材料股份有限公司公开发行可转换公司债券的批复》核准，重庆正川医药包 装材料股份有限公司（以下简称"公司"）于2021年4月28日公开发行可转换公司 债券405万张，每张面值人民币100元，本次发行可转换公司债券募集资金总额为 人民币405,000,000元，期限6年（即自2021年4月28日至2027年4月27日），债券 票面年利率为：第一年0.50%、第二年0.70%、第三年1.20%、第四年1.80%、第五 年2.40%、第六年3.00%。 根据《上海证券交易所股票上市规则》和《重庆正川医药包装 ...

重要内容提示： 投资者可于 2023 年 05 月 10 日(星期三) 至 05 月 16 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zczq@cqzcjt.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 重庆正川医药包装材料股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 17 日 上午 10:00-11:30 举行业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 | 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-027 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 董事会秘书：刘茜 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 225,554,847.36, representing a year-on-year increase of 0.41%[3] - The net profit attributable to shareholders decreased by 49.85% to CNY 12,994,745.54 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses also fell by 49.72% to CNY 10,786,507.71[3] - The basic and diluted earnings per share were both CNY 0.09, down by 47.06% year-on-year[3] - Total revenue for Q1 2023 was CNY 225,554,847.36, a slight increase of 0.41% compared to CNY 224,626,184.94 in Q1 2022[14] - Net profit for Q1 2023 was CNY 12,994,745.54, a decrease of 49.8% from CNY 25,910,867.89 in Q1 2022[15] - The total comprehensive income for the first quarter of 2023 was CNY 12,994,745.54, compared to CNY 25,910,867.89 in the same period of 2022, indicating a decrease of approximately 49.8%[16] - Basic earnings per share for Q1 2023 were CNY 0.09, down from CNY 0.17 in Q1 2022, reflecting a decline of 47.1%[16] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 173.13% to CNY 39,221,086.61, mainly due to the maturity of bank acceptance bills[3][6] - Net cash flow from operating activities for Q1 2023 was CNY 39,221,086.61, a significant improvement from a net outflow of CNY 53,634,995.93 in Q1 2022[19] - Cash inflow from operating activities totaled CNY 237,657,119.10 in Q1 2023, compared to CNY 164,902,876.84 in Q1 2022, representing an increase of approximately 43.9%[19] - Cash outflow from operating activities decreased to CNY 198,436,032.49 in Q1 2023 from CNY 218,537,872.77 in Q1 2022, a reduction of about 9.2%[19] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was CNY 141,004,035.98, down from CNY 313,825,947.96 at the end of Q1 2022, a decrease of approximately 55.1%[20] - The company experienced a net decrease in cash and cash equivalents of CNY 42,430,805.71 in Q1 2023, compared to a decrease of CNY 33,960,475.67 in Q1 2022, indicating ongoing liquidity challenges[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,011,134,906.46, a slight increase of 0.17% from the end of the previous year[4] - The company's total assets as of March 31, 2023, were CNY 2,011,134,906.46, compared to CNY 2,007,660,704.19 at the end of 2022[13] - Current assets totaled CNY 998,774,958.70, slightly up from CNY 991,745,118.14 at the end of 2022[12] - Total liabilities decreased to CNY 813,941,668.09 from CNY 823,465,211.36 at the end of 2022[13] - Cash and cash equivalents were CNY 182,611,697.04, down from CNY 212,432,533.40 at the end of 2022[12] - Accounts receivable increased to CNY 185,523,812.16 from CNY 141,283,714.62 at the end of 2022[12] - Inventory decreased to CNY 200,654,515.22 from CNY 209,426,565.25 at the end of 2022[12] Shareholder Information - The company reported a total of 23,842 common shareholders at the end of the reporting period[8] - The largest shareholder, Chongqing Zhengchuan Investment Management Co., Ltd., holds 39.07% of the shares[9] Government Support - The company received government subsidies amounting to CNY 931,555.48, which are closely related to its normal business operations[5] Research and Development - The company reported a decrease in research and development expenses to CNY 4,126,878.25 from CNY 4,888,245.32 in Q1 2022[15] Investment Activities - The net cash flow from investing activities was negative CNY 81,111,616.31 in Q1 2023, compared to a positive CNY 19,920,770.27 in Q1 2022, indicating a significant shift in investment strategy[19] - The company reported cash received from the recovery of investments amounting to CNY 110,000,000.00 in Q1 2023, an increase from CNY 100,000,000.00 in Q1 2022[19] Accounting Standards - The company plans to implement new accounting standards starting January 1, 2023, which may impact financial reporting and performance metrics going forward[20]

Financial Performance - In 2022, the company's operating revenue was CNY 796,198,292.56, a slight decrease of 0.06% compared to CNY 796,657,258.00 in 2021[23] - The net profit attributable to shareholders of the listed company for 2022 was CNY 64,765,035.84, down 39.25% from CNY 106,603,635.45 in 2021[23] - The net cash flow from operating activities decreased by 63.39% to CNY 38,426,207.67 in 2022, compared to CNY 104,966,819.34 in 2021[23] - The basic earnings per share for 2022 were CNY 0.43, a decrease of 39.44% from CNY 0.71 in 2021[24] - The weighted average return on equity decreased to 5.51% in 2022, down 4.15 percentage points from 9.66% in 2021[24] - The net cash flow from operating activities was negative in the first quarter at -53,634,995.93 RMB, but turned positive in the second quarter at 65,304,832.03 RMB[26] - Non-recurring gains and losses amounted to 7,086,079.07 RMB in 2022, with government subsidies contributing 5,057,327.65 RMB[28] - The company reported a net cash flow from operating activities of 38.43 million RMB, a decrease of 63.39% from the previous year[42] - Financial expenses increased by 259.34% to 14.82 million RMB, primarily due to increased bond interest expenses[42] Assets and Liabilities - The total assets of the company at the end of 2022 were CNY 2,007,660,704.19, an increase of 2.41% from CNY 1,960,497,669.74 at the end of 2021[23] - The net assets attributable to shareholders of the listed company increased by 1.56% to CNY 1,184,195,492.83 at the end of 2022[23] - The company's debt-to-asset ratio increased slightly to 41.02% from 40.53% in the previous year[162] - Total liabilities increased to $823,465,211.36 from $794,529,117.74, marking an increase of around 3.6%[200] - Current liabilities rose to $389,663,830.12 compared to $378,182,939.67, an increase of about 2.9%[200] - Non-current liabilities totaled $433,801,381.24, up from $416,346,178.07, reflecting a growth of approximately 4.0%[200] Production and Market Development - The company made significant progress in the market layout of borosilicate products, adding over 100 potential new customers[34] - Sales performance remained stable, with oral liquid products achieving record sales and injection products showing a year-on-year growth trend[34] - The first borosilicate furnace underwent technical upgrades, leading to improved quality and production capacity[34] - The company initiated the second borosilicate furnace, further consolidating its technology and enhancing competitive production capabilities[34] - Continuous upgrades and optimization of production equipment were implemented to improve efficiency and reduce costs[34] - The company is actively expanding its production capacity for borosilicate glass tubes and bottles to meet growing market demand[36] Research and Development - Research and development expenses increased by 58.22% to 19.11 million RMB, reflecting a stronger focus on innovation[42] - The total R&D investment for the period was 47,540,569.07 yuan, representing 5.97% of the operating income[58] - The company has 261 R&D personnel, making up 14.60% of the total workforce[59] - The company is committed to enhancing its research and development capabilities to continuously upgrade production processes and meet increasing regulatory standards[75] Strategic Partnerships and Customer Base - The company has formed deep strategic partnerships with over 600 domestic clients, including major pharmaceutical enterprises[39] - The company’s top five customers accounted for 30.05% of total annual sales, indicating a reliance on a limited customer base[54] - The total revenue from its top two customers was 9,925.86 million yuan, accounting for 12.51% of the annual total sales[55] Environmental and Sustainability Initiatives - The company invested CNY 1,364,000 in environmental protection during the reporting period[116] - The company has established a comprehensive environmental protection system and internal control framework to mitigate environmental risks[117] - The company reported no instances of exceeding pollutant discharge standards during the reporting period[118] - The company has implemented carbon reduction measures, including the adoption of all-oxygen combustion technology, which is expected to reduce energy consumption and carbon emissions[125] - The company achieved a suspended solid discharge concentration of 17.7 mg/L, significantly below the limit of 70 mg/L[119] Governance and Management - The company held 2 shareholder meetings during the reporting period, ensuring compliance with legal regulations and protecting the rights of minority investors[81] - The board of directors convened 8 meetings, adhering to relevant laws and regulations to ensure scientific decision-making and protect shareholder interests[81] - The supervisory board held 7 meetings, fully complying with legal requirements to oversee the company's lawful operations[81] - The company actively communicated with minority shareholders to keep them informed about significant developments and to gather feedback for the board of directors[82] - The company strictly followed information disclosure obligations, ensuring transparency and accuracy in reporting[82] Future Outlook and Risks - The company has outlined potential risks in its future development plans, which investors should be aware of[9] - The company faces potential risks from policy changes that may raise packaging material standards, requiring ongoing investment in technology and production upgrades[75] - The company is dependent on the pharmaceutical industry, and any downturn in this sector could directly impact its performance and demand for packaging materials[76] - The company recognizes the risk of product substitution as new materials may emerge in the pharmaceutical packaging industry, potentially affecting demand for its glass packaging products[76] Shareholder Information - Chairman Deng Yong held 29,305,364 shares at the beginning and end of the year, with a pre-tax remuneration of 862,500 CNY[86] - Director Jiang Hui, who left the position, increased her indirect shareholding from 0 to 2,145,790 shares, with a pre-tax remuneration of 223,400 CNY[86] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.2946 million yuan[90] - The company has undergone changes in its board and management, with several members leaving and new appointments made, including the hiring of a new general manager[91]

证券代码：603976 证券简称：正川股份 重庆正川医药包装材料股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------------|--------------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | 投资者关系活动 | □特定对象调研 □分析师会议 | | | | 类别 | □媒体采访 ...

2022 年第三季度报告 证券代码：603976 证券简称：正川股份 重庆正川医药包装材料股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 2022 年第三季度报告 | 套期保值业务外，持有交易性金融资 | | | | --- | --- | --- | | 产、衍生金融资产、交易性金融负债、 | | | | 衍生金融负债产生的公允价值变动 | | | | 损益，以及处置交易性金融资产、衍 | | | | 生金融资产、交易性金融负债、衍生 | | | | 金融负债和其他债权投资取得的投 | | | | 资收益 | | | | 单独进 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 410,426,279.38, representing a 26.66% increase compared to CNY 324,046,563.10 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was CNY 40,521,108.84, a 4.56% increase from CNY 38,753,502.80 in the previous year[18]. - Basic earnings per share for the first half of 2022 were CNY 0.27, a 3.85% increase from CNY 0.26 in the same period last year[19]. - The net profit after deducting non-recurring gains and losses was CNY 36,123,306.46, which is a 10.16% increase from CNY 32,791,974.69 in the same period last year[18]. - The total operating revenue for the first half of 2022 reached ¥410,426,279.38, a 26.7% increase from ¥324,046,563.10 in the same period of 2021[107]. - Net profit for the first half of 2022 was ¥40,521,108.84, representing a 4.5% increase compared to ¥38,753,502.80 in the previous year[108]. - The total comprehensive income for the current period is CNY 11,472,379.41[130]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 85.91%, amounting to CNY 11,669,836.10 compared to CNY 82,816,659.02 in the same period last year[18]. - The company's cash and cash equivalents decreased by 38.03% to ¥243,019,441.35 from ¥392,168,152.34, indicating a significant investment in projects[36]. - The company’s cash flow from operating activities showed a negative trend, indicating potential challenges in operational efficiency[116]. - The total cash and cash equivalents at the end of the period decreased to 14,490,772.77 RMB from 199,955,006.27 RMB in the previous year[116]. - The total assets at the end of the reporting period were CNY 1,946,995,568.39, a decrease of 0.69% from CNY 1,960,497,669.74 at the end of the previous year[18]. - The company’s total assets as of June 30, 2022, amounted to CNY 1,946,995,568.39, a slight decrease from CNY 1,960,497,669.74 at the beginning of the year[102]. - The company’s total liabilities and owner's equity at the end of the current period is CNY 1,038,284,781.14[133]. Investments and R&D - Research and development expenses increased by 112.42% to ¥12,208,150.76 from ¥5,747,119.42, reflecting a significant investment in innovation[31]. - The company is actively expanding its production capacity for borosilicate glass products to meet increasing market demand[24]. - The company incurred a net cash outflow from investing activities of RMB 113,877,920.82, compared to a net outflow of RMB 59,221,422.36 in the same period last year[113]. - The company has 31 patent technologies, including 2 invention patents, showcasing its commitment to technological innovation[30]. Market Position and Strategy - The company is a leading player in the pharmaceutical packaging materials industry, focusing on the production of medicinal glass containers[23]. - The company has established four production bases and operates fourteen furnaces, making it one of the largest manufacturers in the medicinal glass container sector[27]. - The company has formed deep strategic partnerships with over 600 domestic clients, including major pharmaceutical manufacturers[28]. - The company is focusing on upgrading its product structure towards high-end products and enhancing technological improvements[26]. - The company plans to continue its market expansion strategies, although specific figures were not disclosed in the call[128]. Risks and Challenges - The company faces potential policy risks as national standards for pharmaceutical packaging materials may be raised, aligning more closely with those in developed countries[40]. - The company relies heavily on the pharmaceutical industry, and any slowdown in this sector could directly impact its operating performance[40]. - The company is exposed to risks related to product quality issues from downstream clients, which could adversely affect sales and production[41]. - The company’s performance is significantly affected by fluctuations in the prices of raw materials and energy, which are critical to its production[42]. Environmental Compliance - The company has established a comprehensive environmental protection system and is classified as a key pollutant discharge unit, ensuring compliance with environmental standards[49]. - The company has ongoing construction projects, including the second phase of the Zhengchuan Yongcheng project and a borosilicate medicinal glass production project, both of which are currently under environmental impact assessment[53]. - The company implemented upgrades to the 4 and 5 full oxygen kiln technology, which is expected to reduce energy consumption and carbon emissions[56]. - The company has a self-monitoring plan in place and has engaged a third-party testing agency to monitor wastewater and exhaust emissions, with results showing all pollutant indicators meet standards[55]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 27,488[81]. - The largest shareholder, Chongqing Zhengchuan Investment Management Co., holds 59,077,736 shares, representing 39.07% of total shares[83]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[71]. - The company has made commitments to avoid any competition with its controlling shareholders and actual controllers[67]. Accounting and Financial Reporting - The financial statements are prepared on a going concern basis, with no significant doubts about the company's ability to continue operations for the next 12 months[140]. - The company adheres to the accounting standards, ensuring that the financial statements accurately reflect its financial position and operating results[142]. - The company recognizes loss allowances for financial instruments based on a combination of individual and portfolio assessments[157]. - Revenue recognition principles involve assessing contracts to identify performance obligations and determining when control of goods or services is transferred to customers[189].

Financial Performance - In 2021, the company's operating revenue reached CNY 796,657,258, representing a 58.70% increase compared to CNY 501,981,691 in 2020[22]. - The net profit attributable to shareholders of the listed company was CNY 106,603,635, a 100.95% increase from CNY 53,050,474 in the previous year[22]. - The basic earnings per share for 2021 was CNY 0.71, up 102.86% from CNY 0.35 in 2020[23]. - The total assets of the company increased by 48.01% to CNY 1,960,497,669.74 at the end of 2021, compared to CNY 1,324,609,139.70 at the end of 2020[22]. - The company's net assets attributable to shareholders increased by 12.07% to CNY 1,165,968,552 at the end of 2021[22]. - The net profit after deducting non-recurring gains and losses was CNY 92,449,315.57, a 96.11% increase from CNY 47,140,758.18 in 2020[22]. - The company achieved a revenue of 796.66 million RMB in 2021, representing a 58.70% increase compared to the previous year[31]. - The company reported a 50.11% increase in operating costs, primarily due to the corresponding rise in revenue[41]. - The company achieved a main business revenue of 793.62 million yuan in 2021, an increase of 58.60% compared to the previous year[43]. - The operating cost for the same period was 591.69 million yuan, reflecting a 50.04% increase year-over-year[43]. Cash Flow and Investments - The net cash flow from operating activities was CNY 104,966,819.34, a decrease of 13.82% from CNY 121,794,840.68 in 2020[22]. - The net cash flow from operating activities for the first quarter was 16.71 million RMB, while the fourth quarter saw a decrease to 8.78 million RMB[26]. - The company’s investment activities generated a net cash flow increase due to the utilization of idle funds for investments[43]. - The company received funds from issuing convertible bonds, contributing to the net cash flow from financing activities[43]. Production and Market Expansion - The company successfully issued 4.05 million convertible bonds, raising a total of 405 million RMB for projects related to borosilicate glass production and compatibility research[31]. - The production capacity of borosilicate products significantly increased, with the first borosilicate furnace reaching production efficiency and a second furnace project initiated[31]. - The company is advancing its international strategy by building multiple overseas sales platforms and expanding its international market presence[31]. - The company expanded its high-end pharmaceutical packaging market by establishing strategic partnerships with several well-known pharmaceutical companies[31]. - The revenue from the North China region increased significantly by 422.23% year-over-year, indicating strong market performance[46]. Research and Development - The company has a total of 31 patented technologies, including 2 invention patents, enhancing its research and development capabilities[38]. - The company has increased its research and development expenses to 12.08 million RMB, a rise of 46.34% compared to the previous year, indicating a focus on innovation[41]. - The company is focusing on digital transformation in its workshops to enhance production management and efficiency[31]. - The company is committed to continuous improvement in organizational mechanisms and employee capability enhancement[31]. Risks and Challenges - The company has outlined potential risks in its future development strategy, which investors should consider[8]. - The company recognizes the risk of dependency on the pharmaceutical industry, which could impact its performance if the industry experiences a downturn[73]. - The company is aware of potential risks related to product quality issues from downstream clients, which could adversely affect its sales[74]. - The company is facing significant price competition in the bulk procurement segment, leading to a substantial decrease in winning bid prices, which will increase supply chain and quality risks[68]. - The company anticipates a trend of stronger players dominating the market, as larger firms with better financing and technology capabilities will increasingly partner with pharmaceutical companies[68]. Corporate Governance - The company held one shareholders' meeting during the reporting period, ensuring compliance with legal regulations and protecting minority shareholders' rights[79]. - The board of directors convened eight meetings, adhering to relevant laws and regulations to ensure sound decision-making and protect shareholder interests[79]. - The supervisory board held seven meetings, fully complying with legal requirements to oversee the company's operations[79]. - The company maintains transparent performance evaluation and incentive mechanisms for its directors and managers, linking compensation to industry standards and company performance[80]. - The company actively communicates with minority shareholders to keep them informed about significant developments and gather feedback for board consideration[81]. Environmental Responsibility - The company has established a comprehensive environmental protection system and internal control framework, effectively reducing environmental risks[114]. - Key pollutants such as Chemical Oxygen Demand (COD) and Ammonia Nitrogen were reported at 86 mg/L and 2.28 mg/L respectively, both within the emission standards[115]. - The company constructed a wastewater treatment station and has operational facilities for dust removal and denitrification, achieving compliant pollutant discharge[116]. - The company implemented a full oxygen kiln technology transformation, expected to reduce energy consumption and carbon emissions[122]. - No administrative penalties were reported during the reporting period due to environmental issues[121]. Shareholder Information - The total number of shares held by directors and senior management at the end of the reporting period is 40,198,294 shares, unchanged from the beginning of the year[84]. - The total pre-tax remuneration for directors and senior management during the reporting period amounts to 503.45 million yuan[84]. - The company has a diverse board with a mix of male and female directors, including 3 independent directors[84]. - The company’s chairman, Deng Yong, holds 29,305,364 shares, representing a significant stake[84]. - The actual controllers of the company, including Mr. Deng Yong, Ms. Jiang Hui, and Mr. Deng Qiuhan, have pledged not to interfere in the company's management or infringe on its interests[132].